Table of Contents

HK J Paediatr (New Series)
Vol 22. No. 3, 2017

HK J Paediatr (New Series) 2017;22:144-150

Original Article

BK Virus-associated Haemorrhagic Cystitis in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation: A Single Institution Experience

TH Jaing, PK Tsay, TY Chang, YC Wen, YC Yang, SH Chen, YC Tian


Background: BK virus-associated haemorrhagic cystitis (BKV-HC) has emerged as a serious infection after haematopoietic stem cell transplantation. The purpose of this study is to determine the incidence, risk factors, and outcome of BKV-HC. Procedure: We investigated the incidence, risk factors and outcome of BKV-HC in 207 paediatric patients undergoing first allogeneic haematopoietic stem cell transplantation over a 10-year period. BKV-HC was defined as BK virus (BKV) detection in urine by PCR testing in association with genitourinary symptoms. Thirty-three patients were tested for BKV because of symptoms indicative of haematuria during the study period. Results: Twenty-three patients were diagnosed with BKV-HC at our institution. The cumulative incidence of BKV-HC in our series was 11.1%. The median age at diagnosis was 12.8 years (range: 5.8-18.6). The median time to haemorrhagic cystitis (HC) was 22 days (range: 4-42). The dose of cyclosporine was decreased as required to maintain the graft. Most patients received myeloablative conditioning regimens (92%) and there was a trend toward higher grade of HC in cord blood transplant recipients. Univariate and multivariate analyses showed that older age (p<0.001) was significantly related to BKV-HC. All patients survived without sequelae except for one who succumbed to multi-organ failure. Conclusion: The majority of patients recover with conservative treatment. However, these conclusions should be regarded as preliminary in view of the retrospective and nonrandomised nature of this study.

Keyword : Allogeneic haematopoietic stem cell transplantation; BK virus; Haemorrhagic cystitis

Abstract in Chinese


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2022 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.